ArticleNature medicine2026
Global and regional cancer burden attributable to modifiable risk factors to inform prevention.
Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Mapping Psychosocial Determinants for Cancer Onset: An Umbrella Review.Psycho-oncology · 2026Pooled it
- A review of the relationship between dimensions of alcohol consumption and the burden of disease: 2026 update including Mendelian randomisation studies.Addiction (Abingdon, England) · 2026Pooled it
- Cancer risk perception among family members of patients with digestive tract cancer and associated patient- and family member-related factors: A cross-sectional study of 414 patient-family member pairs.Asia-Pacific journal of oncology nursing · 2026Article
- Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026Review
- SRSF3 plays a key role in liver cancer sex disparity by facilitating hepatocyte expression of ERα and FOXA.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- GLP-1 Receptor Agonists and Colorectal Cancer Outcomes: Hype, Hope, or Hidden Confounding?Annals of surgical oncology · 2026Article
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.The Lancet. Oncology · 2026Article
- Review
- Disparities in Cancer Incidence by Sex and Associated Lifestyle Factors and Health Conditions.JAMA oncology · 2026Article
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modifiable lifestyle factors and cancer risk in Latin America: A systematic review with meta-analysis.iScience · 2026Article
- A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.BJC reports · 2026Article
- Inhibitory effects of c-MYC degrading rLON protease on intestinal polyps in PIRC rat, a familial adenomatous polyposis model.Neoplasia (New York, N.Y.) · 2026Article
- Projected preventable cancers through full implementation of tobacco control policies in East and South-East Asian countries, 2025-2050: a modeling study.The Lancet regional health. Western Pacific · 2026Article
- Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Journal of gastrointestinal oncology · 2026Article
- Cancer and Health Inequalities.British journal of cancer · 2026Review
- Awareness and Knowledge Levels of Cervical Cancer and HPV and Attitudes Toward HPV Vaccination in Algeria.Vaccines · 2026Article
- Article
- Early-onset cancer in Latin America: incidence trends, evidence gaps and clinical implications.EClinicalMedicine · 2026Review
- Attributing climate-related health burdens in Southeast Asia: a scoping review.The Lancet regional health. Western Pacific · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a leading cause of morbidity globally, largely attributable to modifiable risks. We estimated the 2022 global and national cancer burden attributable to 30 such factors, including tobacco smoking, alcohol consumption, high body mass index, insufficient physical activity, smokeless tobacco and areca nut, suboptimal breastfeeding, air pollution, ultraviolet radiation, 9 infectious agents and 13 occupational exposures, to inform prevention efforts. Using GLOBOCAN data for 36 cancer sites in 185 countries, we applied prevalence data from around 2012 to reflect exposure-cancer latency and estimated Levin-based or Miettinen-based population-attributable fractions (PAFs) or direct estimates where applicable. Combined PAFs accounting for overlapping exposures were derived by cancer, sex, country and region. In 2022, an estimated 7.1 million of 18.7 million new cancer cases (37.8%) were attributable to 30 modifiable risk factors-2.7 million (29.7%) in women and 4.3 million (45.4%) in men. The proportion of preventable cancers ranged from 24.6% to 38.2% in women and from 28.1% to 57.2% in men across regions. Smoking (15.1%), infections (10.2%) and alcohol consumption (3.2%) were the leading contributors to cancer burden. Lung, stomach and cervical cancers represented nearly half of preventable cancers. Strengthening efforts to reduce modifiable exposures remains central to global cancer prevention.
Indexed as
Identifiers
41634393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.